Experimental cocktail aims to boost immune attack on childhood brain tumors
NCT ID NCT05106296
First seen Jan 11, 2026 · Last updated Jun 15, 2026 · Updated 23 times
Summary
This early-phase trial tests whether adding ibrutinib to an existing immunotherapy and chemotherapy regimen can safely improve treatment for children and young adults (ages 6–25) with brain cancers like medulloblastoma or glioblastoma that have come back or not responded to standard therapy. Participants receive ibrutinib plus indoximod and one of two chemotherapy combinations. The goal is to find the best dose and see if the combination shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Augusta University, Georgia Cancer Center
RECRUITINGAugusta, Georgia, 30912, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.